State Street Corp lifted its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX – Free Report) by 1.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,098,062 shares of the company’s stock after buying an additional 15,569 shares during the quarter. State Street Corp’s holdings in Nkarta were worth $4,963,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Wasatch Advisors LP lifted its position in Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock valued at $8,293,000 after purchasing an additional 442,125 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Nkarta by 11,164.3% in the second quarter. Acadian Asset Management LLC now owns 303,461 shares of the company’s stock worth $1,792,000 after buying an additional 300,767 shares during the period. Marshall Wace LLP raised its holdings in Nkarta by 136.7% during the 2nd quarter. Marshall Wace LLP now owns 439,973 shares of the company’s stock valued at $2,600,000 after buying an additional 254,104 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Nkarta during the 2nd quarter valued at $1,489,000. Finally, Affinity Asset Advisors LLC bought a new stake in Nkarta in the 2nd quarter worth $1,182,000. 80.54% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on NKTX. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. HC Wainwright dropped their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a report on Monday, November 11th. Rodman & Renshaw initiated coverage on Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective on the stock. Needham & Company LLC decreased their target price on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 8th. Finally, Mizuho dropped their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.00.
Nkarta Trading Down 0.4 %
NKTX opened at $2.41 on Monday. The company has a market cap of $170.07 million, a price-to-earnings ratio of -1.28 and a beta of 0.82. The stock has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $4.51. Nkarta, Inc. has a 12-month low of $2.08 and a 12-month high of $16.24.
About Nkarta
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Read More
- Five stocks we like better than Nkarta
- What Are Some of the Best Large-Cap Stocks to Buy?
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Election Stocks: How Elections Affect the Stock Market
- These 3 Quirky ETFs May Be Strong Plays in 2025
- What is the Dogs of the Dow Strategy? Overview and Examples
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX – Free Report).
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.